Investor Presentation

Top shareholders Share price Pro-inflammatory chemokines • • • • • ✓ ✓ ✓ ✓ ✓ ✓ 1. If patent applications are granted: PCT/AU2022/050013; 2. DMX-200 is a New Chemical Entity (NCE): an active moiety not approved before which can attract exclusivity periods in various territories 3. Granted patents US9,314,450; US10,058,555; US10,525,038; CN2012800046165; CA2,821,985; EP12734251.7; HK 4104477.8; IL227414; JP2013-547780; SA203/5897; AU2012206945 • • • • • ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ❑ ❑ ❑ ❑ ❑ ✓ ❑ Phase 2a DMX-200-202 (ACTION for FSGS): Phase 2a, Double-blind, Randomised, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of DMX-200 in Patients with Primary Focal Segmental Glomerulosclerosis who are Receiving Irbesartan • Primary endpoint: safety. Secondary endpoint: proteinuria and biomarker analysis. • Patient population: Patients with primary FSGS who are receiving irbesartan Study period 1 16 weeks Washout 6 weeks Study Period 2 16 weeks Results Group 1 (n=5) DMX-200 Placebo Group 2 (n=5) Placebo DMX-200 Angiotensin receptor blocker • • ▪ ▪ PPG Placebo -50 -40 -30 -20 -10 0 Change in PCR ratio (%) Geometric mean difference -17% (95% CI -43 to +20; p0.25) DMX-200 • o o o • •

The release as fetched from its publisher. dimerix.com ↗